Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma

Autor: Besse, Lenka, Besse, Andrej, Stolze, Sara C., Sobh, Amin, Zaal, Esther A., Ham, Alwin J.Van Der, Ruiz, Mario, Phuyal, Santosh, Buchler, Lorina, Sathianathan, Marc, Florea, Bogdan I., Boren, Jan, Hlman, Marcus Sta, Huber, Julia, Bolomsky, Arnold, Ludwig, Heinz, Hannich, J. Thomas, Loguinov, Alex, Everts, Bart, Berkers, Celia R., Pilon, Marc, Farhan, Hesso, Vulpe, Christopher D., Overkleeft, Herman S., Driessen, Christoph, Veterinaire biochemie, Sub Biomol.Mass Spectrometry & Proteom., dB&C FR-RMSC RMSC, Biomolecular Mass Spectrometry and Proteomics

Publikováno v: Cancer Research, 81(17), 4581. American Association for Cancer Research Inc.
Cancer Research, 81(17), 4581-4593
Cancer Res
Cancer Research, 81(17), 4581-4593. AMER ASSOC CANCER RESEARCH

The HIV-protease inhibitor nelfinavir has shown broad anticancer activity in various preclinical and clinical contexts. In patients with advanced, proteasome inhibitor (PI)–refractory multiple myeloma, nelfinavir-based therapy resulted in 65% parti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f215420f1fa944c3e920aa0a755b256a
https://doi.org/10.1158/0008-5472.can-20-3323